Found Weight Loss: Who It's Best For and What to Expect

What Is Found and Is It a Legitimate Medical Platform?

Found is a legitimate, physician-staffed telehealth company focused on weight management. It connects patients with licensed clinicians who can assess medical history, order labs through partner diagnostic networks, and prescribe FDA-approved weight-loss medications. The platform is not a supplement shop or a wellness app dressed up as a clinic.

The U.S. Obesity treatment field changed substantially after the FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in June 2021, followed by tirzepatide (Zepbound) in November 2023. Wegovy prescribing information Those approvals made GLP-1 receptor agonists the most clinically supported drug class for obesity outside of bariatric surgery. Found was among the telehealth platforms that expanded GLP-1 access after those approvals.

How Found Handles Prescribing

Found clinicians follow FDA-labeled indications. GLP-1 agonists are indicated for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. FDA label for semaglutide 2.4 mg Patients who do not meet those thresholds are typically offered non-GLP-1 medications or declined for prescription treatment.

What "Legit" Means Clinically

A telehealth platform is considered clinically legitimate when its prescribers follow evidence-based protocols, obtain informed consent, screen for contraindications, and have a process for managing adverse events. Found states it follows those standards. Independent verification is limited because telehealth companies are not required to publish their clinical protocols. Patients should ask their Found clinician directly for the decision criteria used in their treatment plan.

The Found Ideal Patient Profile

Not every person who wants to lose weight is the right fit for Found. The patients who tend to get the most from the platform share a specific set of characteristics.

Clinical Eligibility Criteria

The clearest fit is an adult aged 18 or older with a BMI of 30 or higher, or a BMI between 27 and 29.9 plus a documented comorbidity. That matches the FDA indication for approved GLP-1 agents. The 2023 American Heart Association scientific statement on obesity and cardiovascular disease explicitly frames obesity as a chronic disease requiring long-term medical management, not a lifestyle choice. AHA 2023 obesity statement Patients who meet that clinical threshold and have a primary care physician who is either unavailable for obesity medicine or simply time-constrained often find Found fills a real access gap.

Insurance and Cost Sensitivity

Found has negotiated arrangements with Blue Cross Blue Shield plans that can reduce membership fees for eligible enrollees. A patient with BCBS coverage who cannot get a GLP-1 prescription covered through their own primary care practice may find Found's infrastructure useful for prior authorization navigation. Patients with no insurance, or with plans that exclude obesity medications, will face high out-of-pocket drug costs regardless of which platform they use. Semaglutide 2.4 mg lists at roughly $1,349 per month without insurance, a number that applies equally whether the prescription originates from Found or from a hospital-based obesity clinic.

Behavioral and Engagement Profile

Found includes asynchronous coaching as part of the membership. Patients who respond well to text-based check-ins and who can self-monitor food intake and activity without weekly face-to-face accountability tend to do better on the platform than those who need intensive behavioral support. The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo, but that trial paired medication with in-person counseling every four weeks. STEP-1, New England Journal of Medicine, 2021 Found's coaching model is lighter than that protocol, which may narrow the real-world weight loss gap between the medication's pharmacological ceiling and what patients actually achieve on the platform.

Who Should Look Elsewhere

Patients with a personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are contraindicated for GLP-1 agonists per FDA labeling. Patients with active eating disorders, specifically anorexia nervosa or bulimia nervosa, require specialist-level psychiatric and nutritional oversight that a telehealth platform cannot reliably provide. Patients with type 1 diabetes, recent bariatric surgery, or active pancreatitis need monitoring intensity that exceeds what a mail-order prescription model offers.

What Medications Does Found Prescribe?

Found prescribes both GLP-1 medications and a range of non-GLP-1 options, making it one of the broader-formulary telehealth weight-loss platforms available in 2025.

GLP-1 Receptor Agonists

Semaglutide (Wegovy for weight, Ozempic off-label for weight) and liraglutide (Saxenda) are the two GLP-1 agents most commonly associated with Found's formulary. Tirzepatide (Zepbound) prescribing through telehealth platforms expanded through 2024. Each of these agents carries FDA approval for chronic weight management with distinct dose titration schedules. Saxenda FDA label

The SCALE Obesity trial (N=3,731) showed liraglutide 3.0 mg produced 8.4% mean weight loss at 56 weeks versus 2.8% with placebo, a smaller effect than semaglutide in STEP-1. SCALE Obesity, NEJM, 2015 Clinicians on Found who follow the evidence would reasonably prefer semaglutide over liraglutide when insurance coverage is equal, given the superior efficacy data.

Non-GLP-1 Prescription Options

Found distinguishes itself from GLP-1-only platforms by offering:

• Bupropion-naltrexone (Contrave): A combination dopamine/norepinephrine and opioid antagonist approved for chronic weight management. The COR-I trial (N=1,742) showed 6.1% weight loss at 56 weeks with bupropion-naltrexone versus 1.3% with placebo. COR-I, Lancet, 2010
• Topiramate: An anticonvulsant with off-label weight loss use; commonly paired with phentermine in the FDA-approved combination Qsymia.
• Metformin: Off-label for weight management; evidence base includes the Diabetes Prevention Program (N=3,234), which showed metformin reduced diabetes progression by 31% and produced modest weight loss of roughly 2.1 kg over 2.8 years. DPP, NEJM, 2002
• Phentermine: A Schedule IV stimulant approved for short-term obesity treatment.

The breadth of the formulary matters because not every patient is a candidate for a GLP-1 agent. A patient with a history of severe major depression stabilized on an SSRI, for example, might be a reasonable candidate for bupropion-naltrexone only after a careful psychiatric review.

Compounded Semaglutide: A Critical Caveat

During the 2022 to 2024 period of Wegovy shortage, many telehealth platforms, including some Found-affiliated pharmacies, dispensed compounded semaglutide. The FDA removed semaglutide from the drug shortage list in February 2025, after which compounding of semaglutide in most 503B outsourcing facilities became impermissible. FDA shortage resolution notice Patients receiving compounded semaglutide through Found or any other platform after that date should confirm the legal and regulatory status of that specific compounding pharmacy. The FDA has issued multiple warnings about inaccurate dosing in compounded GLP-1 products.

How Does Found Compare to Alternatives?

The table below summarizes how Found positions against four commonly considered alternatives across the dimensions that matter most to a prospective patient. This framework was developed by the HealthRX medical team based on publicly available prescribing information, pricing, and published clinical protocols as of January 2025.

| Platform | GLP-1 Access | Non-GLP-1 Rx | In-Person Option | Insurance Integration | Starting Membership Cost | |---|---|---|---|---|---| | Found | Yes | Yes (broad) | No | BCBS partnerships | ~$99/month | | Ro (Body) | Yes | Limited | No | Limited | ~$99/month | | Noom Med | Yes | Limited | No | Some plans | ~$70/month + Rx | | WeightWatchers Clinic | Yes | Limited | No | Some plans | ~$84/month | | Obesity medicine specialist (in-person) | Yes | Yes (broad) | Yes | Most major insurers | Copay-based; varies |

Key clinical difference: An in-person obesity medicine board-certified physician (ABOM-certified) can order and interpret laboratory panels, perform physical exams, and coordinate care with endocrinologists, cardiologists, and behavioral health specialists. None of the telehealth platforms fully replicate that coordination capacity. The Obesity Medicine Association guidelines recommend a comprehensive evaluation including thyroid function, fasting lipids, fasting glucose or HbA1c, and liver enzymes before initiating pharmacotherapy. Obesity Medicine Association clinical guidelines Found's model relies on patients self-reporting labs or ordering through partner services, which introduces a documentation gap.

Where Found Has a Real Advantage

Found's BCBS partnership structure is a genuine differentiator for patients in those networks. Many primary care physicians deprioritize obesity medicine during 15-minute office visits, and referral wait times to academic obesity centers can exceed three months. For a patient who meets the clinical criteria, has BCBS coverage, and needs to start pharmacotherapy sooner rather than later, Found closes an access gap that the traditional system creates.

Where Found Lags

The asynchronous coaching model lacks the structure of behavioral interventions shown to amplify medication outcomes. The STEP-5 trial (N=304) demonstrated that semaglutide 2.4 mg sustained 15.2% weight loss at 104 weeks with behavioral counseling support. STEP-5, Nature Medicine, 2022 Platforms that pair synchronous, therapist-led behavioral therapy with GLP-1 prescribing are likely to produce better long-term outcomes for patients with significant emotional eating patterns.

How Much Does Found Cost?

Pricing has two components: the membership fee and the medication cost. These are often conflated in patient reviews, which distorts the real cost picture.

Membership Fees

Found's membership is priced at approximately $99 per month as of early 2025. That fee covers the clinical consultation, the prescriber relationship, and access to the coaching platform. It does not cover medication.

Medication Costs

Medication cost depends entirely on insurance. For patients with insurance coverage for obesity pharmacotherapy:

• Semaglutide 2.4 mg (Wegovy): copay as low as $0 with manufacturer savings cards for commercially insured patients; list price approximately $1,349/month.
• Liraglutide 3.0 mg (Saxenda): similar list price range; manufacturer copay support available.
• Bupropion-naltrexone (Contrave): generic bupropion and naltrexone separately prescribed may cost significantly less than the brand combination.
• Metformin: generic; typically under $10/month at most pharmacies.

For patients without drug coverage, GLP-1 medications prescribed through Found cost the same as those prescribed anywhere else. The platform does not offer its own compounding pharmacy (post-FDA shortage resolution), and it does not have manufacturer contracts that reduce list prices.

Total Annual Cost Estimate

A patient paying $99/month for membership and using Contrave (bupropion-naltrexone) at approximately $60/month generic equivalent would spend roughly $1,908 per year before any insurance offset. A patient on semaglutide 2.4 mg without insurance could spend over $17,000 per year in medication costs alone on top of the membership. That number shapes the calculus significantly.

What Do Found Patient Reviews Actually Tell Us?

Patient reviews are not clinical evidence, but they contain signal worth acknowledging. Across aggregated review platforms, Found receives consistent praise for prescription access speed and the breadth of non-GLP-1 options. Common criticisms include billing confusion around the membership versus medication costs, delays in prior authorization support, and variability in clinician engagement quality.

Reading Reviews Critically

Reviews skew toward extreme experiences. Patients who lose significant weight or who feel their access to medication was life-changing leave positive reviews. Patients who encounter prior authorization denials, insurance disputes, or medication side effects that were poorly managed leave negative reviews. The modal patient experience sits in neither extreme.

The FDA's 2023 Consumer Update on telehealth weight-loss services noted that patients should confirm their telehealth prescriber is licensed in their state and that the platform has a clear adverse event reporting pathway. FDA consumer update on telehealth weight-loss Found meets those baseline criteria, but patients should ask for their prescriber's name and license number at intake.

What Reviews Cannot Tell You

No patient review can tell you whether the medication a platform prescribed was appropriate for your specific metabolic profile. The 2023 American Diabetes Association Standards of Care note that GLP-1 receptor agonist selection should account for cardiovascular risk, renal function, and HbA1c targets when diabetes is present. ADA Standards of Care 2023 A review saying "I lost 30 pounds" does not confirm that the medication prescribed was the right choice, the right dose, or monitored correctly.

Practical Steps Before Signing Up for Found

A patient considering Found should complete four steps before submitting payment information.

First, confirm your BMI and document any comorbidities. Gather a recent blood pressure reading, a fasting glucose or HbA1c result if available, and any prior weight-loss medication history. Found's intake questionnaire will ask for this information, and having it ready accelerates the clinical review.

Second, contact your insurer before enrolling. Ask specifically whether your plan covers FDA-approved obesity medications and whether Found's clinicians are in-network for the purposes of prescription authorization. BCBS partnership does not mean all BCBS plans cover Found's services identically.

Third, review the contraindication list for GLP-1 agents. If you have a personal or family history of medullary thyroid carcinoma, MEN2, active gallbladder disease, or a history of pancreatitis, disclose that during intake and ask the clinician how those factors affect your treatment options.

Fourth, set realistic weight-loss expectations anchored to trial data. STEP-1 produced 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg, but that was a controlled trial with structured behavioral support. Real-world weight loss in telehealth settings is likely to be lower, with one retrospective analysis of a commercial GLP-1 telehealth cohort reporting approximately 8 to 10% body weight reduction at 52 weeks in patients who remained on therapy.

Patients who complete those four steps before enrolling are better positioned to evaluate whether Found's model matches their clinical situation, rather than discovering a mismatch after the first billing cycle.